Peficitinib improves bone fragility by recovering bone turnover imbalance in arthritic mice
Authors:
Open Access
- 1 January 2022
- journal article
- research article
- Published by Elsevier in Journal of Pharmacological Sciences
- Vol. 148 (1) , 134-141
Abstract
No abstract availableKeywords
Funding Information
- Astellas Pharma
- Astellas Pharma Inc
This publication has 31 references indexed in Scilit:
- Resolution of inflammation induces osteoblast function and regulates the Wnt signaling pathwayArthritis & Rheumatism, 2011
- Evidence for osteocyte regulation of bone homeostasis through RANKL expressionNature Medicine, 2011
- Matrix-embedded cells control osteoclast formationNature Medicine, 2011
- TLR-3 enhances osteoclastogenesis through upregulation of RANKL expression from fibroblast-like synoviocytes in patients with rheumatoid arthritisImmunology Letters, 2009
- Soluble RANKL Induces High Bone Turnover and Decreases Bone Volume, Density, and Strength in MiceCalcified Tissue International, 2008
- Bone Quality — The Material and Structural Basis of Bone Strength and FragilityNew England Journal of Medicine, 2006
- The Roles of Bone Mineral Density, Bone Turnover, and Other Properties in Reducing Fracture Risk During Antiresorptive TherapyMayo Clinic Proceedings, 2005
- TNF-α antibodies and osteoprotegerin decrease systemic bone loss associated with inflammation through distinct mechanisms in collagen-induced arthritisBone, 2004
- A new modality for immunosuppression: targeting the JAK/STAT pathwayNature Reviews Drug Discovery, 2004
- The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritisArthritis & Rheumatism, 1988